ATP1A3 and alternating hemiplegia of childhood: In engineered HEK293T cells and induced pluripotent stem cells (iPSCs) derived from patients with AHC, we developed PE and BE strategies that efficiently correct (40%–90% in treated iPSCs) five ATP1A3 mutations that together cause more than 65% of ATP1A3-associated AHC cases.